Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.

BACKGROUND AND METHODS Mutations in the estrogen-receptor gene have been thought to be lethal. A 28-year-old man whose estrogen resistance was caused by a disruptive mutation in the estrogen-receptor gene underwent studies of pituitary-gonadal function and bone density and received transdermal estrogen for six months. Estrogen-receptor DNA, extracted from lymphocytes, was evaluated by analysis of single-strand-conformation polymorphisms and by direct sequencing. RESULTS The patient was tall (204 cm [80.3 in.]) and had incomplete epiphyseal closure, with a history of continued linear growth into adulthood despite otherwise normal pubertal development. He was normally masculinized and had bilateral axillary acanthosis nigricans. Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal. Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased. Glucose tolerance was impaired, and hyperinsulinemia was present. The bone mineral density of the lumbar spine was 0.745 g per square centimeter, 3.1 SD below the mean for age-matched normal women; there was biochemical evidence of increased bone turnover. The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration. Conformation analysis of his estrogen-receptor gene revealed a variant banding pattern in exon 2. Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon. The patient's parents were heterozygous carriers of this mutation, and pedigree analysis revealed consanguinity. CONCLUSIONS Disruption of the estrogen receptor in humans need not be lethal. Estrogen is important for bone maturation and mineralization in men as well as women.

[1]  Y. Ito,et al.  Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Chrousos,et al.  Syndromes of Glucocorticoid Resistance , 1993, Annals of Internal Medicine.

[3]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Mcdermott,et al.  Thyroid hormone resistance syndromes. , 1993, The American journal of medicine.

[5]  D. Eyre,et al.  A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  J. Bilezikian,et al.  Urinary pyridinium crosslinks of collagen Specific markers of bone resorption in metabolic bone disease , 1992, Trends in Endocrinology & Metabolism.

[7]  A. Elias,et al.  Hormone pattern in pharmacologically feminized male transsexuals in the California State prison system. , 1992, Journal of the National Medical Association.

[8]  K. Schieweck,et al.  Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  A. Klibanski,et al.  Osteopenia in men with a history of delayed puberty. , 1992, The New England journal of medicine.

[10]  M. Shozu,et al.  A new cause of female pseudohermaphroditism: placental aromatase deficiency. , 1991, The Journal of clinical endocrinology and metabolism.

[11]  J. Boyd,et al.  Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations , 1991, Molecular carcinogenesis.

[12]  F. S. French,et al.  Functional characterization of naturally occurring mutant androgen receptors from subjects with complete androgen insensitivity. , 1990, Molecular endocrinology.

[13]  M. Grumbach,et al.  Clinical review 14: Pathophysiology and treatment of sexual precocity. , 1990, The Journal of clinical endocrinology and metabolism.

[14]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[15]  O. Pescovitz,et al.  Treatment of familial male precocious puberty with spironolactone and testolactone. , 1989, The New England journal of medicine.

[16]  B. V. VON Schoultz,et al.  A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy , 1989, The Prostate.

[17]  P. Chambon,et al.  Genomic organization of the human oestrogen receptor gene. , 1988, The EMBO journal.

[18]  M. Young,et al.  Male hypogonadism and bone fracture. , 1988, The New England journal of medicine.

[19]  C. Longcope,et al.  Androgenic and estrogenic metabolites in serum of mice fed dehydroepiandrosterone: relationship to antihyperglycemic effects. , 1987, Metabolism: clinical and experimental.

[20]  W. Crowley,et al.  Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism , 1987 .

[21]  A. Prader,et al.  Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. , 1986, The Journal of pediatrics.

[22]  C. Foresta,et al.  Osteoporosis and decline of gonadal function in the elderly male. , 1984, Hormone research.

[23]  R. Barbieri,et al.  Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. , 1983, American journal of obstetrics and gynecology.

[24]  J. Wilson,et al.  Origin of estrogen in normal men and in women with testicular feminization. , 1979, The Journal of clinical endocrinology and metabolism.

[25]  H. DeLuca,et al.  Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. , 1978, The New England journal of medicine.